Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 2Available 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 2

Conditions

Osteosarcoma 2

Interventions

Ifosfamide 17Methotrexate 16Doxorubicin 14Filgrastim 13Etoposide 12Cisplatin 12Cyclophosphamide 10Gemcitabine 9Leucovorin 8Sirolimus 6Carboplatin 6Topotecan 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Temozolomide 4Sorafenib 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Docetaxel 4trimetrexate glucuronate 3temsirolimus 3dinutuximab 3cixutumumab 3apatinib 3Vincristine 3Specimen Handling 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Osteosarcoma × mifamurtide × Clear all
NCT01459484 2024-05-20

ISG/OS-2

Italian Sarcoma Group

Phase 2 Completed
225 enrolled
Sarcoma

Osteosarcoma

NCT00631631 2014-05-14

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

Millennium Pharmaceuticals, Inc.

Completed
205 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡